Seres Therapeutics Inc (NAS:MCRB)
$ 0.915 0.038 (4.33%) Market Cap: 156.22 Mil Enterprise Value: 176.53 Mil PE Ratio: 0 PB Ratio: 6.54 GF Score: 47/100

Q3 2022 Seres Therapeutics Inc Earnings Call Transcript

Nov 02, 2022 / 12:30PM GMT
Release Date Price: $8.19 (-9.50%)
Operator

Good morning. My name is Colby and I will be your conference operator today. At this time, I would like to welcome everyone to the Third Quarter 2022 Seres Therapeutics, Inc. Earnings Conference Call. (Operator Instructions) Thank you. I will now turn the call over to Dr. Carlo Tanzi, Head of Investor Relations.

Carlo Tanzi
Seres Therapeutics, Inc. - IR Officer

Thank you, and good morning. Our press release for the company's third quarter 2022 financial results and business update became available at 7:00 a.m. Eastern time this morning and can be found on the Investors and News section of the company's website. I'd like to remind you that we'll be making forward-looking statements, including the potential approval and launch of investigational SER-109 in its status first-in-class oral therapeutic. The anticipated indication for SER-109, the potential for microbiome therapeutics to protect against infection, the use of cash to fund operations, and other statements which are not historical fact. Actual results may differ materially. Additionally, these statements

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot